Sayar, Hamid <br/><br/>
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.  [electronic resource] 

 -  Leukemia research  Aug 2011 
 - 1108-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2011.02.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Anemia--drug therapy<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Apoptosis--drug effects<br/>Azacitidine--therapeutic use<br/>Erythroid Precursor Cells--drug effects<br/>Erythropoiesis--drug effects<br/>Erythropoietin--therapeutic use<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--complications<br/>Prognosis<br/>bcl-X Protein--metabolism